Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

• Главные авторы: Xiaoting Liu (Автор), Xiao-xue Liu (Автор), Wenqing Shao (Автор), Yi Zhou (Автор), Jing Zhang (Автор), Cuirong Zhao (Автор), Chengwu Shen (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

ObjectiveBoth camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of local advanced or metastatic sqNSCLC. However, the co...